Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
To determine the mechanism of symptom relief with treatment by botulinum toxin injection in persons with adductor spasmodic dysphonia (ADSD), we evaluated the effects of unilateral thyroarytenoid muscle injections on both injected and noninjected muscles in 10 subjects with ADSD, using electromyography on both sides of the larynx before and after treatment. The subjects' speech symptoms were reduced (p = .005) 2 weeks following injection, when the electromyographic study occurred. Muscle activation levels and the numbers of spasmodic muscle bursts decreased significantly (p < or = .03) postinjection in both the injected and noninjected muscles. The reductions in laryngeal muscle bursts correlated with symptom reduction (r > or = .7) in all muscles. Reductions in laryngeal muscle bursts did not relate to either absolute or normalized levels of muscle activity before or after botulinum toxin injection. The results suggest that changes in the central pathophysiology are responsible for changes in speech symptoms following treatment.
Bielamowicz
S
S
Laryngeal and Speech Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Ludlow
C L
CL
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004576:Electromyography; D005260:Female; D006801:Humans; D007821:Laryngeal Muscles / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D014832:Voice Disorders / Q000188:drug therapy* / Q000503:physiopathology
D019274:Botulinum Toxins, Type A